{"schema_version":"1","generated_at":"2026-10-29T23:00:18.603Z","data_as_of":null,"url":"https://www.findmykol.com/kol/philip-amrein","json_url":"https://www.findmykol.com/kol/philip-amrein/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"philip-amrein","name":"Philip Amrein","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Harvard University","institution_url":"https://www.findmykol.com/institution/harvard-university","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1073589578","orcid":"0000-0001-7770-2623","openalex":"A5009091754"},"summary":"Philip Amrein is an Oncology physician affiliated with Harvard University. OpenAlex indexes 224 publications with 4,871 citations (h-index 34); ClinicalTrials.gov lists 6 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":224,"cited_by_count":4871,"h_index":34,"latest_activity_year":2025,"source":"works"},"trials":{"count":6,"shown":3,"withheld":3,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT02582359","title":"MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"Massachusetts General Hospital","source_url":"https://clinicaltrials.gov/study/NCT02582359","trial_url":"https://www.findmykol.com/trial/NCT02582359"},{"nct":"NCT02228772","title":"Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"Massachusetts General Hospital","source_url":"https://clinicaltrials.gov/study/NCT02228772","trial_url":"https://www.findmykol.com/trial/NCT02228772"},{"nct":"NCT01173679","title":"Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Massachusetts General Hospital","source_url":"https://clinicaltrials.gov/study/NCT01173679","trial_url":"https://www.findmykol.com/trial/NCT01173679"}],"source":"trials"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":3,"shown":3,"withheld":0,"rows":[{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":132.96,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1073589578"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2024,"amount_usd":13.44,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1073589578"},{"payer":"AstraZeneca UK Limited","program_year":2022,"amount_usd":55,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1073589578"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1073589578","source":"payments"},"prescribing":{"data_year":2024,"areas_total":4,"areas_shown":3,"areas":[{"area":"Musculoskeletal","share_pct":35.6,"classes_total":1,"classes":[{"class":"Xanthine oxidase inhibitor","setting":"prescribed","share_pct":35.6,"drugs":[{"name":"Allopurinol","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":24.7,"classes_total":1,"classes":[{"class":"Antimetabolite","setting":"prescribed","share_pct":24.7,"drugs":[{"name":"Hydroxyurea","share_pct":100}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":23.3,"classes_total":1,"classes":[{"class":"Benzodiazepine","setting":"prescribed","share_pct":23.3,"drugs":[{"name":"Lorazepam","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-6","status":"verified"},{"title":"Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i> -Mutated Acute Myeloid Leukemia","year":2023,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-23-0182","status":"verified"},{"title":"Clinical response to larotrectinib in adult Philadelphia chromosome–like ALL with cryptic ETV6-NTRK3 rearrangement","year":2020,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2019000769","status":"verified"},{"title":"An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study","year":2019,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(19)30030-4","status":"verified"},{"title":"Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy","year":2019,"journal":"Leukemia","source_url":"https://doi.org/10.1038/s41375-019-0449-1","status":"verified"}],"source":"works"},"contact":{"address_1":"55 FRUIT ST YAW 7","address_2":"HEMATOLOGY ONCOLOGY","city":"Boston","state":"MA","zip":"02114","phone":"617-726-8748","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1073589578","source":"identity"},"similar":[{"name":"Felipe Fregni","slug":"felipe-fregni","institution":"Harvard University","specialty":"Neurology","url":"https://www.findmykol.com/kol/felipe-fregni","json_url":"https://www.findmykol.com/kol/felipe-fregni/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Sarah Fortune","slug":"sarah-fortune","institution":"Harvard University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/sarah-fortune","json_url":"https://www.findmykol.com/kol/sarah-fortune/profile.json"},{"name":"Ethan Lerner","slug":"ethan-lerner","institution":"Harvard University","specialty":"Dermatology","url":"https://www.findmykol.com/kol/ethan-lerner","json_url":"https://www.findmykol.com/kol/ethan-lerner/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":3,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-09-11","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}